The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma
Official Title: Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma-- A Nationwide Multicentered Prospective Controlled Study
Study ID: NCT05844813
Brief Summary: The goal of this clinical trial is to explore the potential survival benefits of neoadjuvant chemotherapy combined with target treatments followed by radical surgery in patients with primary high-risk/grade retroperitoneal sarcoma. The main questions it aims to answer are: * Whether the 1,3-year progression-free survival time(PFS) is prolonged in the neoadjuvant therapy group, compared with the surgery-only group. * The Overall survival time in the two groups. * The safety and tolerance in the neoadjuvant therapy group. Participants will be allocated into two groups once they meet the inclusion criteria. * Surgery-only Group: Patients will directly undergo surgeries after the confirmation of diagnosis through pre-operative biopsy. * Neoadjuvant therapy group: Patients will receive the neoadjuvant chemotherapy combined with target treatment for three circles before the following sarcoma resectional surgeries.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Beijing Friendship Hospital, Beijing, Beijing, China
Peking University First Hospital, Beijing, Beijing, China
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Shanghai Cancer Hospital, Minhang Branch, Shanghai, Shanghai, China
Shanghai Zhongshan Hospital, Shanghai, Shanghai, China
First Affiliated Hospital Xi'an Jiaotong University, Xi'an, Shanxi, China
Name: Chenghua Luo, MD, PhD
Affiliation: Peking University International Hospital
Role: STUDY_CHAIR